Anuh Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹185 Cr −0.5% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
AP

Anuh Pharma Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Anuh Pharma Q3 FY26: Revenue ₹201.18 Cr, PAT ₹13.45 Cr

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹197Cr
+23.1% YoY
+5.9% QoQ
Net profit
₹13Cr
+30% YoY
+62.5% QoQ
Margin
10%
+1 pp YoY
+4 pp QoQ

Based on Anuh Pharma Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹91
Market cap₹937 Cr
P/E21.2

The short version

Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) - Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6) - Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33) - Commentary (page 6): "Revenue sustained strong momentum" and outlook expects year-end as per budget estimates with improving pricing, capacity expansion, higher utilization, and operational efficiencies driving sustainable margin improvements (pages 6 & 7). EBITDA (Q3 FY26): ₹20.91 Cr, up 62.63% QoQ (from ₹12.86 Cr) - Operating Margin (Q3 FY26): 23.28% (stated on Page 6), compared to 22.24% in the previous quarter - Profit After Tax (PAT, Q3 FY26): ₹13.45 Cr, up 76.70% QoQ (from ₹7.61 Cr) - Year-on-Year (9M FY26 vs 9M FY25) figures (Page 13): - EBITDA down 5.66% YoY to ₹47.45 Cr (from ₹50.29 Cr) - PAT down 15.85% YoY to ₹29.36 Cr (from ₹34.89 Cr) - Explicit Margin Outlook (Page 7 & 34): - Expectation of sustainable margin improvement driven by capacity expansion, higher utilization, operational efficiencies, improved pricing, and cost optimization.

From Anuh Pharma Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr)
  • Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6)
  • Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33)
  • Commentary (page 6): "Revenue sustained strong momentum" and outlook expects year-end as per budget estimates with improving pricing, capacity expansion, higher utilization, and operational efficiencies driving sustainable margin improvements (pages 6 & 7).

Profitability & Margins

See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capacity expansion efforts have supported increased revenues and stronger product mix (Page 6).
  • The company emphasizes continuing capacity expansion and higher utilization to drive sustainable margin improvement in upcoming quarters (Page 7).
  • Strategic expansion plan includes pursuing selective inorganic growth opportunities alongside disciplined capital expenditure to strengthen product portfolio and market presence (Page 7).
  • A dedicated 10,000 sq. ft. in-house R&D facility with 16 scientists is operational for developing new products and processes to support future market penetration and product pipeline expansion (Page 32).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It provides the following relevant insights: - The outlook mentions that "The order position and demand is good" indicating a positive and healthy order status. (Page 7) - The company expects to end the year as per budget estimates, which implies stable order inflow supporting revenue forecasts. (Page 7)

Anuh Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anuh Pharma Ltd Q3 FY26 results — key figures

Anuh Pharma Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue197160+23.1%186+5.9%
Operating profit (EBITDA)1915+26.7%12+58.3%
Operating margin10%9%+1 pp6%+4 pp
Profit before tax1813+38.5%10+80%
Net profit (PAT)1310+30%8+62.5%
EPS (₹)1.341.03+30.1%0.76+76.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anuh Pharma Ltd Q3 FY26 results?

Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) - Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6) - Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33) - Commentary (page 6): "Revenue sustained strong momentum" and outlook expects year-end as per budget estimates with improving pricing, capacity expansion, higher utilization, and operational efficiencies driving sustainable margin improvements (pages 6 & 7). EBITDA (Q3 FY26): ₹20.91 Cr, up 62.63% QoQ (from ₹12.86 Cr) - Operating Margin (Q3 FY26): 23.28% (stated on Page 6), compared to 22.24% in the previous quarter - Profit After Tax (PAT, Q3 FY26): ₹13.45 Cr, up 76.70% QoQ (from ₹7.61 Cr) - Year-on-Year (9M FY26 vs 9M FY25) figures (Page 13): - EBITDA down 5.66% YoY to ₹47.45 Cr (from ₹50.29 Cr) - PAT down 15.85% YoY to ₹29.36 Cr (from ₹34.89 Cr) - Explicit Margin Outlook (Page 7 & 34): - Expectation of sustainable margin improvement driven by capacity expansion, higher utilization, operational efficiencies, improved pricing, and cost optimization.

What is Anuh Pharma Ltd share price analysis?

Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.